Literature DB >> 22549784

Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.

Melita Irving1, Vincent Zoete, Michael Hebeisen, Daphné Schmid, Petra Baumgartner, Philippe Guillaume, Pedro Romero, Daniel Speiser, Immanuel Luescher, Nathalie Rufer, Olivier Michielin.   

Abstract

Through a rational design approach, we generated a panel of HLA-A*0201/NY-ESO-1(157-165)-specific T cell receptors (TCR) with increasing affinities of up to 150-fold from the wild-type TCR. Using these TCR variants which extend just beyond the natural affinity range, along with an extreme supraphysiologic one having 1400-fold enhanced affinity, and a low-binding one, we sought to determine the effect of TCR binding properties along with cognate peptide concentration on CD8(+) T cell responsiveness. Major histocompatibility complexes (MHC) expressed on the surface of various antigen presenting cells were peptide-pulsed and used to stimulate human CD8(+) T cells expressing the different TCR via lentiviral transduction. At intermediate peptide concentration we measured maximum cytokine/chemokine secretion, cytotoxicity, and Ca(2+) flux for CD8(+) T cells expressing TCR within a dissociation constant (K(D)) range of ∼1-5 μM. Under these same conditions there was a gradual attenuation in activity for supraphysiologic affinity TCR with K(D) < ∼1 μM, irrespective of CD8 co-engagement and of half-life (t(1/2) = ln 2/k(off)) values. With increased peptide concentration, however, the activity levels of CD8(+) T cells expressing supraphysiologic affinity TCR were gradually restored. Together our data support the productive hit rate model of T cell activation arguing that it is not the absolute number of TCR/pMHC complexes formed at equilibrium, but rather their productive turnover, that controls levels of biological activity. Our findings have important implications for various immunotherapies under development such as adoptive cell transfer of TCR-engineered CD8(+) T cells, as well as for peptide vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22549784      PMCID: PMC3391157          DOI: 10.1074/jbc.M112.357673

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation.

Authors:  Phillip D Holler; David M Kranz
Journal:  Immunity       Date:  2003-02       Impact factor: 31.745

2.  TCRs with high affinity for foreign pMHC show self-reactivity.

Authors:  Phillip D Holler; Lukasz K Chlewicki; David M Kranz
Journal:  Nat Immunol       Date:  2002-12-09       Impact factor: 25.606

3.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.

Authors:  Michael R Betts; Jason M Brenchley; David A Price; Stephen C De Rosa; Daniel C Douek; Mario Roederer; Richard A Koup
Journal:  J Immunol Methods       Date:  2003-10-01       Impact factor: 2.303

4.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

5.  T-cell antagonism by short half-life pMHC ligands can be mediated by an efficient trapping of T-cell polarization toward the APC.

Authors:  Leandro J Carreño; Erick M Riquelme; Pablo A González; Nicolas Espagnolle; Claudia A Riedel; Salvatore Valitutti; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

6.  Evidence for a functional sidedness to the alphabetaTCR.

Authors:  Michael S Kuhns; Andrew T Girvin; Lawrence O Klein; Rebecca Chen; Kirk D C Jensen; Evan W Newell; Johannes B Huppa; Björn F Lillemeier; Morgan Huse; Yueh-Hsiu Chien; K Christopher Garcia; Mark M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-02       Impact factor: 11.205

Review 7.  MM-GBSA binding free energy decomposition and T cell receptor engineering.

Authors:  V Zoete; M B Irving; O Michielin
Journal:  J Mol Recognit       Date:  2010 Mar-Apr       Impact factor: 2.137

8.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.

Authors:  S D Smith; M Shatsky; P S Cohen; R Warnke; M P Link; B E Glader
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

9.  Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time.

Authors:  Milos Aleksic; Omer Dushek; Hao Zhang; Eugene Shenderov; Ji-Li Chen; Vincenzo Cerundolo; Daniel Coombs; P Anton van der Merwe
Journal:  Immunity       Date:  2010-02-04       Impact factor: 31.745

10.  The impact of TCR-binding properties and antigen presentation format on T cell responsiveness.

Authors:  Adam S Chervin; Jennifer D Stone; Phillip D Holler; Ailin Bai; Jianzhu Chen; Herman N Eisen; David M Kranz
Journal:  J Immunol       Date:  2009-06-24       Impact factor: 5.422

View more
  60 in total

1.  Photocrosslinkable pMHC monomers stain T cells specifically and cause ligand-bound TCRs to be 'preferentially' transported to the cSMAC.

Authors:  Jianming Xie; Johannes B Huppa; Evan W Newell; Jun Huang; Peter J R Ebert; Qi-Jing Li; Mark M Davis
Journal:  Nat Immunol       Date:  2012-06-03       Impact factor: 25.606

2.  T cell avidity and tumor immunity: problems and solutions.

Authors:  Arthur A Hurwitz; Steven M Cuss; Katherine E Stagliano; Ziqiang Zhu
Journal:  Cancer Microenviron       Date:  2013-12-20

3.  Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.

Authors:  Stephanie K Dougan; Michael Dougan; Jun Kim; Jacob A Turner; Souichi Ogata; Hyun-Il Cho; Rudolf Jaenisch; Esteban Celis; Hidde L Ploegh
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

4.  Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.

Authors:  Lance M Hellman; Kendra C Foley; Nishant K Singh; Jesus A Alonso; Timothy P Riley; Jason R Devlin; Cory M Ayres; Grant L J Keller; Yuting Zhang; Craig W Vander Kooi; Michael I Nishimura; Brian M Baker
Journal:  Mol Ther       Date:  2018-12-14       Impact factor: 11.454

5.  T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.

Authors:  Shi Zhong; Karolina Malecek; Laura A Johnson; Zhiya Yu; Eleazar Vega-Saenz de Miera; Farbod Darvishian; Katelyn McGary; Kevin Huang; Josh Boyer; Emily Corse; Yongzhao Shao; Steven A Rosenberg; Nicholas P Restifo; Iman Osman; Michelle Krogsgaard
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

6.  2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system.

Authors:  Baoyu Liu; Shi Zhong; Karolina Malecek; Laura A Johnson; Steven A Rosenberg; Cheng Zhu; Michelle Krogsgaard
Journal:  Eur J Immunol       Date:  2013-10-20       Impact factor: 5.532

7.  Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function.

Authors:  Julia T Warren; Wei Zou; Corinne E Decker; Nidhi Rohatgi; Christopher A Nelson; Daved H Fremont; Steven L Teitelbaum
Journal:  J Cell Biochem       Date:  2015-11       Impact factor: 4.429

8.  Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display.

Authors:  Ellen K Wagner; Ahlam N Qerqez; Christopher A Stevens; Annalee W Nguyen; George Delidakis; Jennifer A Maynard
Journal:  J Biol Chem       Date:  2019-02-22       Impact factor: 5.157

Review 9.  To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy.

Authors:  Jessica E Thaxton; Zihai Li
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  SHP-1 phosphatase activity counteracts increased T cell receptor affinity.

Authors:  Michael Hebeisen; Lukas Baitsch; Danilo Presotto; Petra Baumgaertner; Pedro Romero; Olivier Michielin; Daniel E Speiser; Nathalie Rufer
Journal:  J Clin Invest       Date:  2013-02-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.